NCC, Top 3 Japan Makers Form Immunotherapy Consortium with Eye on Alternative to PD-1 Inhibitors

September 20, 2017
The National Cancer Center Hospital East and three major Japanese drug makers, including Takeda Pharmaceutical, are embarking on a large-scale drug discovery collaboration in the immuno-oncology arena, looking to develop and commercialize what could be an alternative to anti-PD-1 antibodies...read more